| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Gianfranco Alpini | |
| Frank Mott | |||
| Arthur-E Frankel | |||
| Matei-P Socoteanu | |||
| P2860 | cites work | HGF/SF-Met signaling in tumor progression | Q36027374 |
| The role of chemotherapy in cholangiocarcinoma | Q36164434 | ||
| Toxin conjugate therapy of cancer | Q36336389 | ||
| A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts | Q40144642 | ||
| Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met | Q40236740 | ||
| Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts | Q40314133 | ||
| Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells | Q40497486 | ||
| Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines | Q40668106 | ||
| Is liver transplantation indicated for cholangiocarcinoma? | Q40797119 | ||
| Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period | Q42635593 | ||
| Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma | Q44860005 | ||
| A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin | Q46402569 | ||
| Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours | Q50163916 | ||
| c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 | ||
| Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap? | Q57272627 | ||
| Chronic Bile Duct Injury Associated with Fibrotic Matrix Microenvironment Provokes Cholangiocarcinoma in p53-Deficient Mice | Q58214837 | ||
| Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers | Q78056476 | ||
| Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys | Q80371652 | ||
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models | Q24629814 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Met receptor tyrosine kinase: enhanced signaling through adapter proteins | Q28140219 | ||
| A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo | Q28183526 | ||
| Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion | Q28184585 | ||
| HGF/SF-met signaling in the control of branching morphogenesis and invasion | Q28202466 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Targeting the c-Met signaling pathway in cancer | Q28246393 | ||
| A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo | Q28270305 | ||
| Targeting the tumor and its microenvironment by a dual-function decoy Met receptor | Q28272715 | ||
| Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors | Q28295039 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial | Q33363800 | ||
| Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy | Q33984809 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase | Q34263863 | ||
| Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation | Q34346870 | ||
| Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature | Q34468865 | ||
| Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 | ||
| Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis | Q34745711 | ||
| Cellular and molecular biology of biliary tract cancers | Q35073918 | ||
| A review and update on cholangiocarcinoma | Q35817693 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| P304 | page(s) | 2990-2994 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | c-Met targeted therapy of cholangiocarcinoma | |
| P478 | volume | 14 |
| Q26784091 | An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma |
| Q38597008 | Cholangiocarcinoma: from molecular biology to treatment |
| Q35919809 | Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal‑regulated kinase signaling pathway |
| Q41231601 | Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy? |
| Q39033749 | Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment |
| Q64085995 | Molecular Pathogenesis of Cholangiocarcinoma |
| Q37878879 | Molecular mechanisms of cholangiocarcinoma |
| Q34391135 | New insights on cholangiocarcinoma. |
| Q55017802 | PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells. |
| Q41073453 | Prognostic Value of C-met Expression in Cholangiocarcinoma |
| Q35108386 | Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma |
| Q42700697 | Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis |
| Q54490877 | Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level. |
| Q41077332 | The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). |
| Q36683019 | The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer |
| Q26865749 | The significance of genetics for cholangiocarcinoma development |
| Q90113516 | Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma |
Search more.